As Africa's healthcare needs grow, demand for innovative treatments for chronic conditions like diabetes is on the rise. This basket offers potential exposure to this trend through leading global pharmaceutical and healthcare companies listed on US and EU exchanges.
Veröffentlicht am September 23
With diabetes and obesity rates rising globally, especially in emerging markets, these companies are positioned at the centre of a massive healthcare transformation that's just getting started.
These aren't just any healthcare companies - they're the ones developing breakthrough treatments and medical technologies that could reshape how we treat chronic conditions worldwide.
As Africa's middle class grows and seeks better healthcare, these established giants have the infrastructure and expertise to capture this expanding market opportunity.
This collection focuses on global healthcare leaders addressing chronic diseases like diabetes and obesity. With Africa's growing middle class seeking better healthcare outcomes, these companies are positioned to benefit from increasing demand for innovative treatments and medical solutions worldwide.
This diversified approach spreads risk across pharmaceutical giants, medical device manufacturers, and healthcare innovators. Rather than betting on a single company, you get exposure to the entire healthcare ecosystem, from drug development to medical equipment and diagnostics.
These companies were handpicked for their leadership in chronic disease management and healthcare innovation. From Novo Nordisk's diabetes expertise to Abbott's diagnostic solutions, each represents a key player in the global healthcare transformation that's particularly relevant for emerging markets.
Market capitalisation breakdown for a healthcare-focused stock basket anchored by large-cap firms.
NVO: $180.85B
LLY: $756.76B
JNJ: $462.30B
Erfahren Sie alles über diesen Aktienkorb. Lesen Sie unseren ausführlichen Artikel zu seinen Risiken und seinem Potenzial.
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
Gilead Sciences has secured FDA approval for a new once-daily HIV combination pill, streamlining therapy for millions of suppressed patients. This regulatory milestone spotlights investment opportunities in pioneering biopharmaceutical companies and drug delivery developers focused on advanced antiviral treatments.
Disney is suing the FCC to block an early license review of its ABC stations, arguing the move is politically motivated retaliation against its news coverage. This unprecedented legal battle highlights the growing regulatory risks for traditional broadcasters and underscores the structural advantages of unregulated digital streaming platforms.
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
Here are a few of the assets in this group. Create an account to unlock the full list.
Join Nemo FREE today and unlock every stock
Es dauert nur 60 Sekunden.
Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitive Ltd.
Wenn Sie in diese Werte investieren:
In 12 Monaten könnte der Wert betragen:
+94.27%
Analysten erwarten im Durchschnitt, dass die Werte dieser Gruppe im nächsten Jahr um 94.27 % zulegen.
8 von 10 Werten dieser Gruppe werden von professionellen Analysten mit „Kaufen“ bewertet.
